Comparing 3 Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation.

IF 5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Journal of the American Heart Association Pub Date : 2025-06-03 Epub Date: 2025-05-22 DOI:10.1161/JAHA.124.039204
Sylvia Lutze, Steve Bachmeier, Alison Bowman, Nicole DeCleene, Hussain Jafari, Matthew Kappel, Caroline Kinuthia, Paulina Lindstedt, Megan Lindstrom, Rajan Mudambi, Christian Razo, Kjell Swedin, Abraham Flaxman, Gregory Roth
{"title":"Comparing 3 Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation.","authors":"Sylvia Lutze, Steve Bachmeier, Alison Bowman, Nicole DeCleene, Hussain Jafari, Matthew Kappel, Caroline Kinuthia, Paulina Lindstedt, Megan Lindstrom, Rajan Mudambi, Christian Razo, Kjell Swedin, Abraham Flaxman, Gregory Roth","doi":"10.1161/JAHA.124.039204","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding the real-world impact of clinical trials that change risk factors is important for health policy. We developed a microsimulation that estimates the population-level benefits in each US state of cardiometabolic interventions.</p><p><strong>Methods: </strong>We designed a state-specific agent-based simulation model with 51 million in silico individuals and estimated results for 2023 to 2040. Input data reflected current cardiometabolic health and the effects of interventions and risk factors. We constructed 3 health policy intervention scenarios based on randomized controlled trials proven to improve cardiometabolic population health: improved access to fixed-dose combination antihypertensive medication, a pharmacist-led intervention with phone-based reminders to increase adherence to statin and antihypertensive medications at the time they are initiated, and a community-based lifestyle and behavior intervention designed to prevent diabetes. Outcomes included CVD events, deaths, and disability-adjusted life years (DALYs).</p><p><strong>Results: </strong>Our simulation included a representative population of the United States, accurate at the age, sex, and state level. By 2040, the fixed-dose combination intervention was estimated to have prevented 776 000 (95% uncertainty interval, 578 000-956 000) CVD DALYs and 44 600 (95% uncertainty interval, 32 700-55 600) deaths annually. The pharmacist-led intervention prevented 170 000 (95% uncertainty interval, 129 000-208 000) CVD DALYs, and the community-based intervention prevented 152 000 (95% uncertainty interval, 128 000-173 000) CVD DALYs.</p><p><strong>Conclusions: </strong>A fixed-dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs. Impact of interventions varied by state. Providing accurate population-level estimates can help local health policy decision-makers implement the most impactful interventions.</p>","PeriodicalId":54370,"journal":{"name":"Journal of the American Heart Association","volume":" ","pages":"e039204"},"PeriodicalIF":5.0000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Heart Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/JAHA.124.039204","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Understanding the real-world impact of clinical trials that change risk factors is important for health policy. We developed a microsimulation that estimates the population-level benefits in each US state of cardiometabolic interventions.

Methods: We designed a state-specific agent-based simulation model with 51 million in silico individuals and estimated results for 2023 to 2040. Input data reflected current cardiometabolic health and the effects of interventions and risk factors. We constructed 3 health policy intervention scenarios based on randomized controlled trials proven to improve cardiometabolic population health: improved access to fixed-dose combination antihypertensive medication, a pharmacist-led intervention with phone-based reminders to increase adherence to statin and antihypertensive medications at the time they are initiated, and a community-based lifestyle and behavior intervention designed to prevent diabetes. Outcomes included CVD events, deaths, and disability-adjusted life years (DALYs).

Results: Our simulation included a representative population of the United States, accurate at the age, sex, and state level. By 2040, the fixed-dose combination intervention was estimated to have prevented 776 000 (95% uncertainty interval, 578 000-956 000) CVD DALYs and 44 600 (95% uncertainty interval, 32 700-55 600) deaths annually. The pharmacist-led intervention prevented 170 000 (95% uncertainty interval, 129 000-208 000) CVD DALYs, and the community-based intervention prevented 152 000 (95% uncertainty interval, 128 000-173 000) CVD DALYs.

Conclusions: A fixed-dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs. Impact of interventions varied by state. Providing accurate population-level estimates can help local health policy decision-makers implement the most impactful interventions.

比较3种减少心血管疾病负担的循证策略:基于个体的心脏代谢政策模拟
背景:了解改变危险因素的临床试验对现实世界的影响对卫生政策很重要。我们开发了一个微观模拟,以估计美国每个州的心脏代谢干预的人群水平的益处。方法:我们设计了一个基于特定状态的基于agent的模拟模型,其中包含5100万计算机个体,并估计了2023年至2040年的结果。输入的数据反映了当前的心脏代谢健康状况以及干预措施和风险因素的影响。基于已证实可改善心脏代谢人群健康的随机对照试验,我们构建了3种卫生政策干预方案:改善获得固定剂量联合抗高血压药物的途径,药剂师主导的干预,通过手机提醒增加他汀类药物和降压药的依从性,以及旨在预防糖尿病的基于社区的生活方式和行为干预。结果包括心血管疾病事件、死亡和残疾调整生命年(DALYs)。结果:我们的模拟包括了美国具有代表性的人口,在年龄、性别和州一级都是准确的。到2040年,估计固定剂量联合干预每年预防了77.6万例(95%不确定区间,57.8万-956万)心血管疾病死亡死亡年和44 600例(95%不确定区间,32 700-55 600)死亡。药剂师主导的干预预防了17万例(95%不确定区间,12.9万~ 20.8万)心血管疾病DALYs,社区干预预防了15.2万例(95%不确定区间,12.8万~ 17.3万)心血管疾病DALYs。结论:固定剂量的抗高血压药物组合可以预防总CVD DALYs的1.2%,依从性和以生活方式为重点的方案的益处较小。干预措施的影响因州而异。提供准确的人口水平估计可以帮助地方卫生政策决策者实施最有效的干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the American Heart Association
Journal of the American Heart Association CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
9.40
自引率
1.90%
发文量
1749
审稿时长
12 weeks
期刊介绍: As an Open Access journal, JAHA - Journal of the American Heart Association is rapidly and freely available, accelerating the translation of strong science into effective practice. JAHA is an authoritative, peer-reviewed Open Access journal focusing on cardiovascular and cerebrovascular disease. JAHA provides a global forum for basic and clinical research and timely reviews on cardiovascular disease and stroke. As an Open Access journal, its content is free on publication to read, download, and share, accelerating the translation of strong science into effective practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信